Whitefort Capital Management LP purchased a new stake in shares of OmniAb, Inc. (NASDAQ:OABI - Free Report) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 10,248,658 shares of the company's stock, valued at approximately $25,211,699. OmniAb makes up 0.0% of Whitefort Capital Management LP's investment portfolio, making the stock its 7th biggest holding. Whitefort Capital Management LP owned about 7.08% of OmniAb at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in shares of OmniAb in the 2nd quarter valued at approximately $21,888,000. Cadian Capital Management LP lifted its position in OmniAb by 20.7% in the 4th quarter. Cadian Capital Management LP now owns 4,434,954 shares of the company's stock worth $8,205,000 after buying an additional 759,386 shares in the last quarter. Woodline Partners LP acquired a new stake in OmniAb in the 3rd quarter valued at approximately $4,571,000. Geode Capital Management LLC lifted its holdings in OmniAb by 17.0% during the 4th quarter. Geode Capital Management LLC now owns 2,722,692 shares of the company's stock valued at $5,038,000 after purchasing an additional 396,456 shares during the last quarter. Finally, Rice Hall James & Associates LLC acquired a new stake in shares of OmniAb during the second quarter worth $6,422,000. 72.08% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several research firms recently weighed in on OABI. HC Wainwright reissued a "buy" rating and set a $11.00 price objective on shares of OmniAb in a report on Monday, August 17th. Weiss Ratings raised shares of OmniAb from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, August 20th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, OmniAb currently has an average rating of "Hold" and a consensus target price of $11.00.
Check Out Our Latest Stock Report on OmniAb
OmniAb Trading Down 2.4%
OABI stock traded down $0.11 during trading on Friday, reaching $4.50. The stock had a trading volume of 731,108 shares, compared to its average volume of 734,340. The company has a market capitalization of $651.52 million, a P/E ratio of -12.50 and a beta of 0.45. The firm has a fifty day moving average price of $2.73 and a 200 day moving average price of $2.18. OmniAb, Inc. has a 1-year low of $1.30 and a 1-year high of $4.93.
OmniAb (NASDAQ:OABI - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.07. The firm had revenue of $13.41 million during the quarter, compared to the consensus estimate of $4.69 million. OmniAb had a negative return on equity of 16.59% and a negative net margin of 115.12%. Sell-side analysts predict that OmniAb, Inc. will post -0.35 EPS for the current year.
OmniAb Profile
(
Free Report)
OmniAb, Inc NASDAQ: OABI operates as a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s integrated antibody discovery platform combines proprietary transgenic animal models, in vitro screening, and in silico engineering to accelerate lead identification and optimization. OmniAb offers both fee-for-service collaborations and license agreements, enabling biopharmaceutical partners to leverage its suite of technologies for programs spanning oncology, immunology, and other therapeutic areas.
Founded in 2016 and headquartered in Seattle, Washington, OmniAb went public in May 2021.
Featured Stories
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider OmniAb, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OmniAb wasn't on the list.
While OmniAb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
